ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC).

Fiche publication

Date publication

décembre 2025

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie

Tous les auteurs :
Roupret M, Bertaut A, Pignot G, Neuzillet Y, Houede N, Mathieu R, Corbel L, Besson D, Seisen T, Jaffrelot L, Lebacle C, Champiat S, Lebdai S, Timsit MO, Thibault C, Goeman L, Soto ÁJ, La C, Léger C, Loriot Y

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41110692

Résumé

Standard treatment for high-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT) is intravesical instillation with Bacillus Calmette-Guérin (BCG) (induction and maintenance regimens); however, BCG therapy still fails in 30 to 40% of patients. Prior studies suggest that programmed death-ligand 1 (PD-L1) expression and alterations in immune infiltration might be associated with BCG failure.